Azenosertib: New Median Duration of Response Data in Platinum-Resistant Ovarian Cancer
In the ongoing DENALI Part 1b clinical trial, the investigational agent Azenosertib, a selective inhibitor of the Polo-like kinase 1 (PLK1), has recently updated its median duration of response (mDOR) to an impressive 6.3 months in patients with platinum-resistant ovarian cancer (PROC).
Background
Platinum-resistant ovarian cancer (PROC) is a challenging disease to treat due to its inherent resistance to standard chemotherapies. Despite initial responses, most patients eventually relapse, leading to a poor prognosis. Azenosertib, a potential solution, is being investigated as a monotherapy for PROC, and the latest data from the DENALI Part 1b trial offers promising results.
Updated Median Duration of Response
The DENALI Part 1b trial, a multicenter, open-label, single-arm study, enrolled 36 patients with PROC who had received at least 2 prior platinum-based regimens. The primary endpoint of the study was the ORR, defined as the proportion of patients with a complete or partial response. The secondary endpoint was the mDOR, which is the time from the first response assessment to the first documented disease progression.
Objective Response Rate
The study reported an ORR of 35.3% (12 out of 34 response-evaluable patients). This response rate is considered significant, given the poor prognosis of PROC. The ORR was maintained across all subgroups, including those with BRCA wild-type and BRCA mutant tumors.
Median Duration of Response
Regarding the mDOR, the initial data presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program reported a median duration of response of 5.4 months. However, the latest update from the DENALI Part 1b trial shows a significant improvement, with the mDOR now standing at 6.3 months.
Implications for Patients
For patients with PROC, the updated mDOR data for Azenosertib represents a potential new treatment option. While the response rate is not as high as desirable, the median duration of response is a crucial factor for patients, as it indicates how long they can benefit from the treatment before their cancer progresses. Azenosertib’s 6.3-month mDOR is a significant improvement over the standard of care, which often provides limited benefit.
Implications for the World
The updated mDOR data for Azenosertib in PROC has the potential to change the treatment landscape for this disease. Platinum-resistant ovarian cancer is a significant health concern, with limited treatment options and a poor prognosis. Azenosertib, as a selective PLK1 inhibitor, has shown promise in overcoming platinum resistance and extending the duration of response. This could lead to improved outcomes for patients and reduced healthcare costs associated with frequent treatment cycles and disease progression.
Conclusion
The updated median duration of response data for Azenosertib in the DENALI Part 1b clinical trial represents a significant improvement in the treatment of platinum-resistant ovarian cancer. With a response rate of 35.3% and a median duration of response of 6.3 months, Azenosertib offers a potential new treatment option for patients with PROC. The implications for both individual patients and the healthcare system as a whole are substantial, and further research is warranted to confirm these findings and explore the full potential of Azenosertib in the treatment of PROC.
- Azenosertib has updated its median duration of response to 6.3 months in the ongoing DENALI Part 1b clinical trial.
- The ORR for Azenosertib in PROC is 35.3%.
- The updated mDOR for Azenosertib is a significant improvement over standard treatments for PROC.
- Azenosertib’s potential impact on individual patients and the healthcare system is substantial.
